Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Holding JAZZ?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$5.79Last Year’s EPS
$5.02Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 10.24%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected strong performance across Jazz Pharmaceuticals' commercial portfolio, particularly in neuroscience and oncology, with record sales and positive clinical trial results for Zepzelca. However, there were challenges with Rylaze revenue due to updated treatment protocols and a trial setback for Epidiolex in Japan. Overall, the positive financial results and growth prospects balanced out the highlighted challenges.Company Guidance
During the Jazz Pharmaceuticals Q3 2024 earnings call, the company provided guidance that reaffirmed their total revenue and adjusted net income guidance from the previous quarter, despite a $20 million reduction in oncology revenue projections due to protocol updates impacting Rylaze. Total revenue is expected to range between $4 billion and $4.1 billion, indicating a 6% increase from 2023 at the midpoint. Neuroscience revenue is anticipated to be between $2.825 billion and $2.925 billion, reflecting a 3% increase at the midpoint. The company also revised its R&D spending guidance down by $20 million, reflecting strategic pipeline prioritization. Jazz highlighted key growth drivers, including Xywav, Epidiolex, and Rylaze, with continued strong cash flow and a robust financial position to support investments in high-impact products and programs.Strong Commercial Portfolio Growth
Jazz Pharmaceuticals reported strong growth across its commercial portfolio, with record quarterly sales for both Xywav and Epidiolex, and a 9% revenue growth in oncology year-over-year.
Positive Phase III Trial Results
Positive data from the Phase III trial evaluating Zepzelca in first-line maintenance for extensive stage small cell lung cancer was reported, showing significant improvement in overall survival and progression-free survival.
Financial Performance and Guidance
Total revenue for the third quarter of 2024 was over $1.05 billion, a 9% increase compared to the same quarter last year. Adjusted net income increased by 23% year-over-year. Full year revenue guidance is maintained between $4 billion and $4.1 billion.
Epidiolex Approaching Blockbuster Status
Epidiolex achieved net product sales of approximately $252 million in Q3, representing an 18% increase year-over-year, driven by U.S. demand and expansion into new international markets.
---
JAZZ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JAZZ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $111.55 | $119.08 | +6.75% |
| Jul 31, 2024 | $110.25 | $114.38 | +3.75% |
| May 01, 2024 | $110.31 | $109.29 | -0.92% |
| Feb 28, 2024 | $129.70 | $118.90 | -8.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Jazz Pharmaceuticals (JAZZ) report earnings?
Jazz Pharmaceuticals (JAZZ) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Jazz Pharmaceuticals (JAZZ) earnings time?
Jazz Pharmaceuticals (JAZZ) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JAZZ EPS forecast?
JAZZ EPS forecast for the fiscal quarter 2024 (Q4) is $5.79.
---